This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

CACI Completes Acquisition Of Emergint Technologies, Inc.

Stocks in this article: CACI

CACI International Inc ( NYSE: CACI) announced today that it has completed its transaction to acquire Emergint Technologies, Inc., a premier provider of emerging technology solutions focused on the data-driven needs of national health organizations. This acquisition builds on CACI’s healthcare IT capability and expands its presence in the growing healthcare IT market.

Founded in 1999, Emergint has 300 employees and is headquartered in Louisville, Kentucky. The company offers a wide range of healthcare-focused IT-related services that support the missions of federal and state customers. Its workforce has extensive experience providing health data integration and analysis solutions, management and IT consulting, and data and records management. Emergint has contract vehicles with key health-focused federal agencies, including the Centers for Disease Control and Prevention, National Institutes of Health, and U.S. Food and Drug Administration. Its 2012 revenue is expected to be approximately $42 million, and the acquisition is expected to be accretive to CACI’s earnings per share during its first 12 months.

John Mengucci, CACI Chief Operating Officer and President of U.S. Operations, said, “Emergint Technologies, Inc. is a wonderful addition to the CACI team, and their best-in-class capabilities in data analytics, integration, and analysis will greatly enhance our healthcare IT practice. Furthermore, we are positive that their commitment to integrity and client service will make them an excellent fit for our company and culture.”

According to Dan Allen, CACI President and Chief Executive Officer, “As the public health community continually focuses on increasing data information exchange and delivering improved results to enhance patient care, Emergint is a valuable addition to the CACI team. Their established relationships with federal health organizations will help us to further expand our footprint in the high-growth healthcare IT market.”

CACI provides information solutions and services in support of national security missions and government transformation for Intelligence, Defense, and Federal Civilian clients. A member of the Fortune 1000 Largest Companies and the Russell 2000 Index, CACI provides dynamic careers for approximately 14,900 employees working in over 120 offices worldwide. Visit www.caci.com.

There are statements made herein which do not address historical facts, and therefore could be interpreted to be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors that could cause actual results to differ materially from anticipated results. The factors that could cause actual results to differ materially from those anticipated include, but are not limited to, the successful closing and integration of our acquisition of Emergint, actual revenue and earnings realized by Emergint and the performance of the financial management and business services business as well as the risk factors set forth in CACI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2012, and other such filings that CACI makes with the Securities and Exchange Commission from time to time. Any forward-looking statements should not be unduly relied upon and only speak as of the date hereof.

CACI-Acquisition

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,191.37 -195.84 -1.13%
S&P 500 2,002.16 -27.39 -1.35%
NASDAQ 4,637.9940 -43.5030 -0.93%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs